XML 108 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]                    
Income (loss) before income taxes $ 64 $ (923) $ (272) $ (1,185) $ 171 $ (1,178) $ (624) [1],[2] $ (3,163) [1],[2] $ 658 [1],[2]  
Statutory tax rate in Israel             23.00% 23.00% 23.00% 23.00%
Theoretical provision for income taxes [2]             $ (144) $ (727) $ 151  
Increase (decrease) in the provision for income taxes due to:                    
The Parent Company and its Israeli subsidiaries - Tax benefits arising from net deferred taxes, resulting from intellectual property related integration plans, including carryforward losses             (272)      
Tax benefits arising from reduced tax rates under benefit programs             14 15 (12)  
Mainly nondeductible items and prior year tax               35 20  
Non-Israeli subsidiaries, including impairments [3]             372 941 117  
Worthless stock deduction [4]               (909)    
Increase (decrease) in other uncertain tax positions - net             23 2 (65)  
Effective consolidated income taxes $ (12) $ (16) $ (19) $ 149 $ 107 $ (900) $ (7) [2] $ (643) [2] $ 211 [2]  
[1] The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.
[2] The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.
[3] In 2023 and 2022, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.
[4] In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.